FDA发布人用药品设施评估与检查运作概念ConOps 2.0更新版,取代2017年6月版本
FDA更新了对人用药品设施评估与检查的方式
FDA发布《FDA人用药品设施评估与检查项目整合:运作概念》(ConOps 2.0)更新版,取代2017年6月发布的原版。该文件是FDA药品审评与研究中心(CDER)与检查与调查办公室(OII)协调人用药品设施工作的内部协议,新版将远程监管评估(RRAs)正式纳入框架,并把互认协议(MRA)伙伴的检查报告计为评估输入。材料为ECA文章的转述,变化要点引自FDA落地页及行业媒体报道。
The U.S. Food and Drug Administration (FDA) published an updated version of "Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations" (ConOps 2.0). The revised document replaces the original June 2017 version.
美国FDA发布了《FDA人用药品设施评估与检查项目整合:运作概念》(ConOps 2.0)的更新版本。修订后的文件取代了2017年6月发布的原版。
What is the ConOps?
什么是ConOps?
The ConOps is an internal agreement between the FDA's Center for Drug Evaluation and Research (CDER) and its Office of Inspections and Investigations (OII). It defines how the two organisations coordinate their work on human drug facilities.
ConOps是FDA药品审评与研究中心(CDER)与其检查与调查办公室(OII)之间的一项内部协议。它界定了这两个机构在人用药品设施方面如何协调工作。
The aim is to avoid a situation in which the application review and the site inspection run as separate processes with separate information requests. Instead, both are meant to be aligned, so that the agency can take consistent, efficient, and transparent regulatory decisions.
其目的是避免审评申请与现场检查作为两个独立流程、分别提出信息请求的情况。相反,两者应保持一致,以便该机构能够作出一致、高效且透明的监管决定。
The original ConOps was signed in June 2017 by CDER and the Office of Regulatory Affairs (ORA), the field organization that has since been renamed OII. Its central elements were:
最初的《概念文件》由 CDER 和监管事务办公室(ORA)签署,该现场组织后来更名为 OII。其核心要素包括:
Integrated teams that combined CDER reviewers with field investigators
由 CDER 审查员与现场调查员组成的综合团队
Consistent, transparent facility evaluations and regulatory decisions
一致、透明的设施评估和监管决定
A commitment to send facility owners a final classification letter within 90 days after an inspection closes (a GDUFA II commitment), and to complete regulatory actions for facilities with an Official Action Indicated (OAI) status within six months
在检查结束后90天内向设施所有者发出最终分类函(GDUFA II承诺),并在六个月内完成对官方行动指示(OAI)状态设施的监管行动。
What has changed in ConOps 2.0?
ConOps 2.0 有哪些变化?
According to the FDA's landing page and the trade press coverage of the update, the main changes are the following.
根据 FDA 的落地页以及行业媒体对该更新的报道,主要变化如下。
1. Alignment with the FDA reorganization, reflecting the October 2024 reorganization, in which ORA became OII.
与美国FDA的重组保持一致,反映2024年10月的重组,其中ORA变为OII。
2. Remote Regulatory Assessments (RRAs) are formally part of the framework.
远程监管评估(RRAs)正式属于该框架的一部分。
3. Inspection reports from Mutual Recognition Agreement (MRA) partners count as evaluation inputs.
互认协议(MRA)合作伙伴的检查报告可作为评估输入。
4. Clarified roles and responsibilities.
明确职责和责任。
5. Restated objectives
重述的目标
The document now lists five objectives:
该文件现在列出了五个目标:
a risk-based approach to evaluations, inspections, and decisions;
采用基于风险的评估、检查和决策方法;
strategic alignment of CDER and OII functional units;
CDER与OII职能部门的战略协同;
greater operational capacity through less duplication;
通过减少重复工作,提升运营能力;
better quality of and access to facility information across FDA;
提高跨FDA设施信息的质量和获取便利性;
meeting user fee commitments (PDUFA and GDUFA) with shorter regulatory timelines.
通过缩短监管周期,实现与用户费用承诺(PDUFA 和 GDUFA)的对接。
The document also sets out concrete internal timelines: for Preapproval Inspections, Postapproval Inspections, Surveillance Inspections and For-cause Inspections.
该文件还明确了具体的内部时间安排:包括预批准检查、批准后检查、监督检查以及原因检查。
What it means for manufacturers
对制造商的意义
The changes point in one direction: FDA expects to evaluate sites with more information sources, and not only through on-site inspection:
这些变化表明了一个方向:FDA期望通过评估更多信息来源的场所,而不仅仅依赖现场检查。
Expect remote requests: Records requests and virtual walkthroughs may become part of application assessments and surveillance.
预期远程请求:记录请求和虚拟导览可能成为应用程序评估和监控的一部分。
Treat MRA-partner inspections as FDA-relevant: An inspection by an EU or UK authority can now directly shape FDA's view of a site.
将MRA合作伙伴检查视为与FDA相关:欧盟或英国监管机构的检查现在可直接影响FDA对某场所的看法。
Keep the site dossier and data integrity under control: The ConOps remains risk-based. A facility's compliance history, the quality of its application data, and its overall risk profile will continue to determine whether FDA inspects, assesses remotely, or relies on other evidence.
保持现场文件和数据完整性:运营方式(ConOps)仍以风险为基础。设施的合规记录、应用数据的质量以及整体风险状况,将继续决定FDA是进行现场检查、远程评估,还是依赖其他证据。
Include CMOs and CDMOs: Contract manufacturers should be held to the same inspection-readiness expectations as the sponsor's own sites.
包括CMO和CDMO:合同制造商应被要求达到与申办方自身生产设施相同的检验准备要求。
原文来自ECA网站,点击“阅读原文”可查看原文,原文中有该文件的下载链接。
来源:GMP干货 · mp.weixin.qq.com